Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is an extended-spectrum penicillin antibiotic combined with a beta-lactamase inhibitor. It is active against many Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (empiric treatment)
## Adult Dosing
* **Standard Dose:** 3.375 grams (piperacillin 3 grams / tazobactam 0.375 grams) intravenously every 6 hours.
* **Higher Dose:** 4.5 grams (piperacillin 4 grams / tazobactam 0.5 grams) intravenously every 6 or 8 hours for more severe infections or those caused by less susceptible organisms.
* **Maximum Dose:** No explicit maximum dose stated, but dosing typically does not exceed 4.5 grams every 6 hours.
## Pediatric Dosing
* **Pediatric Patients (including term neonates) > 2 months old:** Dosing is based on piperacillin weight.
* **13 years and older:** Same as adult dosing (3.375 g or 4.5 g IV every 6 or 8 hours).
* **2 months to 12 years old:**
* 3.375 g/kg (piperacillin 3 g/kg / tazobactam 0.375 g/kg) IV infused over 30 minutes every 6 hours. **Maximum of 3.375 grams per dose.**
* 4.5 g/kg (piperacillin 4 g/kg / tazobactam 0.5 g/kg) IV infused over 30 minutes every 8 hours. **Maximum of 4.5 grams per dose.**
* **Neonates and Infants < 2 months old:** Dosing in this age group is complex and often guided by institutional protocols and pharmacokinetic data. Common regimens may include 3.375 g/kg IV every 8 hours or 3.375 g/kg IV every 12 hours for premature neonates.
## Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment needed.
* CrCl 20-40 mL/min: Administer 2.25 grams (piperacillin 2 g / tazobactam 0.25 g) or 3.375 grams (piperacillin 3 g / tazobactam 0.375 g) IV every 8 hours.
* CrCl < 20 mL/min: Administer 2.25 grams (piperacillin 2 g / tazobactam 0.25 g) IV every 8 hours.
* Hemodialysis: Administer 2.25 grams (piperacillin 2 g / tazobactam 0.25 g) or 3.375 grams (piperacillin 3 g / tazobactam 0.375 g) IV every 8 hours. An additional dose of 0.75 grams (piperacillin 0.67 g / tazobactam 0.08 g) should be given after each dialysis session.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or beta-lactamase inhibitors.
* History of a severe allergic reaction (e.g., anaphylaxis) to any beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, abdominal pain, constipation, pruritus, elevated liver enzymes (AST, ALT).
* **Serious:** Clostridioides difficile-associated diarrhea, hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome/toxic epidermal necrolysis, seizures (particularly with high doses or renal impairment), interstitial nephritis, hematologic effects (neutropenia, thrombocytopenia).
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance, increasing toxicity.
* **Warfarin:** May decrease the anticoagulant effect of warfarin; monitor INR closely.
* **Live bacterial vaccines:** Efficacy may be reduced.
## Monitoring
* **Renal function:** Especially in patients with known renal impairment or receiving concomitant nephrotoxic agents.
* **Liver function tests:** Baseline and periodic monitoring.
* **Hematologic parameters:** Complete blood count, especially with prolonged therapy.
* **Signs and symptoms of infection:** Clinical response.
* **Signs and symptoms of C. difficile infection.**
* **Electrolytes:** Particularly if administered with potentially interacting fluids or in patients with renal dysfunction.
## Clinical Pearls
* Piperacillin/tazobactam is a broad-spectrum agent often used for empiric therapy of serious infections, including those with potential for beta-lactamase producing organisms.
* Tazobactam inhibits many bacterial beta-lactamases, extending the spectrum of piperacillin.
* Discontinue if hypersensitivity reactions occur.
* Reconstituted solution stability is limited; administer within 24 hours when refrigerated or within 12 hours at room temperature.
* Adjust dose based on renal function.
* Monitor for diarrhea and consider C. difficile infection.
***
*This information is intended for healthcare professionals. It is essential to consult the current prescribing information and relevant clinical guidelines for definitive guidance, as drug information can change.*
